New York Senate Bill S09322

New York 2025-2026 Regular Session

• Introduced: 2/27/26
• Refer: 2/27/26

Caption

Adds 7-Hydroxymitragynine, including its salts, isomers and salts of isomers, as a schedule 1 controlled substance.

Summary

S09322 would amend New York’s Public Health Law to add 7-Hydroxymitragynine, including its salts, isomers, and salts of isomers where applicable, to Schedule I of the state controlled substances schedule. Schedule I classification is reserved for substances treated as having a high potential for abuse and no accepted medical use under state law. The bill is narrowly drafted and does not create a broader regulatory program; it simply places this specific compound into the state’s controlled substances list. The measure would take effect immediately upon enactment. In practical terms, it would make the possession, sale, manufacture, and other controlled-substance activities involving 7-Hydroxymitragynine subject to New York’s existing drug enforcement and criminal penalties applicable to Schedule I substances. The bill appears aimed at closing a gap in the state’s drug scheduling framework by explicitly naming the compound and related chemical forms.

Impact

The bill would amend section 3306 of the Public Health Law, which contains New York’s controlled substances schedules, by adding a new Schedule I entry for 7-Hydroxymitragynine. This would bring the substance and its chemically related forms under the state’s existing prohibitions and enforcement structure for Schedule I drugs, affecting individuals, retailers, manufacturers, and law enforcement agencies that encounter the compound. Because the bill takes effect immediately, the change would apply as soon as it becomes law.

Sentiment

Based on the bill text and available context, the overall sentiment appears to be precautionary and enforcement-oriented, with the sponsor seeking to classify the substance as a dangerous controlled drug. There are no committee transcripts or recorded votes provided, so there is no evidence of formal debate, opposition, or support beyond the introduction of the bill itself.

Contention

No specific points of contention are documented in the available materials. The likely policy issue is whether 7-Hydroxymitragynine should be treated as a Schedule I substance, which generally involves balancing public health and drug enforcement concerns against questions about scientific evidence, medical use, and the scope of criminalization. However, no legislators, advocates, or agencies are quoted in the record provided, so any disagreement remains speculative.